Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 2, 2007, Pages 282-288

  Baronciani, Luciano ^a,b   Federici, A B ^a   Cozzi, G ^a   Canciani, M T ^a   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Expression study; Type1; Type2A; Type2B; Von Willebrand disease

Indexed keywords

ARGININE; COLLAGEN; CYSTEINE; GLYCOPROTEIN IB ALPHA; LEUCINE; PROLINE; RECOMBINANT PROTEIN; RISTOCETIN; THROMBOCYTE RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BINDING AFFINITY; CELL SECRETION; CELL STRAIN COS7; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE CLASSIFICATION; FAMILY STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HYBRID GENE; MALE; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; WILD TYPE;

COLLAGEN; DIMERIZATION; FAMILY HEALTH; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; RECOMBINANT PROTEINS; SIBLINGS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33846440163     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02349.x     Document Type: Article

References (25)

1. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake IR, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand Disease. Thromb Haemost 2000; 84: 160-74.
2. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-97.
3. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-61.
4. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 1-12.
5. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematol 2003; 88: 94-108.
6. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-10.
7. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
8. Ruggeri ZM, Zimmerman TS. Willebrand's disease: Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1272-84.
9. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006; 4: 2088-90.
10. Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood 1992; 79: 2048-55.
11. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, Jorieux S, Mazurier C, the INSERM network on molecular abnormalities in vWD. Gene defects in 150 unrelated French cases with Type 2 von Willebrand disease: From patient to the gene. Thromb Haemostas 1997; 78: 451-6.
12. Casana P, Martinez F, Espinos C, Haya S, Lorenzo JI, Aznar JA. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: New mutations, R1315C and R1341W, associated with type 2M and 2B variants. Am J Hematol 1998; 59: 57-63.
13. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
14. Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibα for the diagnosis of patients with low von Willebrand factor levels. Haematol 2004; 89: 77-85.
15. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302: 1047-51.
16. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-3.
17. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004; 103: 2032-8.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
19. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type-3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40.
20. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histoblood group ABO system. Nature 1990; 345: 229.
21. Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve AC, Peake IR, Daly ME. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood 2000; 96: 560-8.
22. Hilbert L, Gaucher C, De Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
23. Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3: 2689-94.
24. Goodeve AC, Eikenboom JC, Ginsburg D, Hilbert L, Mazurier C, Peake IR, Sadler JE, Rodeghiero F. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost 2001; 85: 929-31.
25. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.